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Introduction
Huntington’s disease (HD) is a neurodegenerative disorder caused by an 
unstable expansion of  the CAG trinucleotide repeat in the Huntingtin (HTT) 
gene for which there is presently no approved disease-modifying therapy.1 
Patients with HD hope for effective treatments to help delay disease onset; 
slow down the clinical progression; and help with problematic motor, cog-
nitive, and psychiatric symptoms. While there is abundant research into 
disease modifying strategies for HD, no currently available treatments have 
been convincingly demonstrated to impact disease progression.2 Thus, 
many patients dealing with neurological disease are known to turn to com-
plementary and alternative medicine (CAM) as a way of  fulfilling the per-
ceived void in effective conventional therapies. CAM includes products that 
are not considered conventional medicine and is broadly classified into four 
categories: (1) alternative medical systems, (2) manipulation/bodywork 
therapies, (3) biologically based therapies, and (4) mind–body therapies.3 
The use of  CAM in HD has never been comprehensively reviewed, and 
the safety and efficacy of  many specific CAM modalities are unclear.
The American Academy of  Neurology (AAN) has published guidelines 
on the pharmacological management of  HD. In a 2012 AAN publication, 
the CAM modalities of  creatine, coenzyme Q10 (CoQ10), and ethyl-EPA 
are reviewed, but no specific guidelines for the use of  other modalities are 
provided.4 Regardless of  available evidence, 44.1% of  US adults with 
neurological conditions reported having used some form of  CAM therapy 
in the past 12 months.5 Specific frequencies of  use in HD are not reported, 
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Abstract
Background: There is a lack of  published guidelines related to the use of  complementary and alternative medicine (CAM) for Huntington’s disease (HD). We 
conducted a review of  the literature to summarize the available evidence for various mind–body practices and nutraceuticals.
Methods: PubMed and Cochrane Library electronic databases were searched independently from inception to February 2019 by two independent raters. Studies 
were classified for the level of  evidence (Class I, II, III, or IV) according to the American Academy of  Neurology (AAN) classification scale.
Results: Randomized controlled trials in HD were reviewed for mind–body interventions (dance therapy, music therapy, and exercise), alternative systems 
( traditional Chinese medicine [TCM]), and nutraceuticals/diet (aminooxyacetic acid [AOAA], coenzyme q10, creatine, cannabinoids, alpha-tocopherol, eicosapen-
taenoic acid, idebenone, levocarnitine, and triheptanoin). Few studies met AAN Class I or II level of  evidence for benefits, and these are highlighted.
Discussion: There is a relative paucity of  clinical trials examining CAM modalities in HD when compared to other neurodegenerative disorders. Currently, there is 
no evidence supporting disease modification or symptom improvement with any specific dietary or nutraceutical supplement for HD. Supervised exercise and contem-
porary dance are safe for people with HD, but more robust studies are warranted to guide specific recommendations for these and other mind–body interventions.
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Neurodegeneration is thought to be in part related to inflamma-
tion, oxidant stress, and mitochondrial dysfunction, which trigger 
complex pathologic downstream cellular effects.6 Aspects of  the 
inflammatory pathway are targets of  industry-sponsored pharmaceu-
tical investigations. Many natural supplements are proposed to have 
helpful antioxidative, anti-inflammatory, and neuroprotective effects 
which may be worthy of  investigation as well.7 Alternative systems 
and mind–body focused interventions are appealing in HD from a 
symptomatic standpoint. HD is characterized clinically by a triad of  
motor, cognitive, and psychiatric-behavioral problems.2 Many CAM 
modalities are suited to influence both the physical as well as the emo-
tional, behavioral, and cognitive aspects of  disease that impact the 
quality of  life.
In order to fulfill a knowledge gap with regard to evi-
dence-based recommendations for CAM use in HD, we conducted a 
review of  the literature to summarize the data related to various 
CAM practices in HD, with specific attention focused on (1) mind–
body interventions and (2) natural products (nutraceuticals and 
dietary changes) given the relative paucity of  evidence for other 
modalities.
Methods
PubMed and Cochrane Library electronic databases were searched 
independently from inception to February 2019. The search was con-
ducted separately by two independent reviewers MY and DB. The 
search terms are provided in Appendix A. These particular CAM 
modalities were queried in the literature review because they have been 
studied in other neurodegenerative diseases like Alzheimer’s disease 
(AD) and Parkinson’s disease (PD). In addition, they are the more com-
monly used modalities with some basis from basic science data.5 Articles 
were restricted to English language publications. Only those articles that 
reported a randomized controlled trial (RCT) design in human subjects 
with HD were included in this review. In total, 37 articles were identi-
fied. All studies were classified for the level of  evidence (Class I, II, III, 
or IV) according to the AAN classification of  level of  evidence.8 Both 
reviewers agreed on the levels of  classification for all studies.
Results
Table 1 shows the breakdown of  RCTs available for review by CAM 
modality, along with the number of  trials meeting level I/II evidence.
Table 1. Breakdown of  RCTs by CAM Modality
Modality/Intervention No. of  RCTs Total No. of  Participants Ref. No. of  Publications with  
Level I/II Evidence (AAN)
Alternative Medical System
Traditional Chinese medicine 1 4 34 0
Mind–Body Interventions
Dance therapy 2 43 18,19 1
Music therapy 3 85 15–17 2
Exercise/physical therapy based 7 303 24–30 6
Nutraceuticals/Dietary Supplementation
Aminooxyacetic acid 1 7 44 1
Cannabinoids 3 88 47–49 3
CoQ10 2 783 42,43 2
Creatine 4 632 51–54 2
d-alpha-tocopherol 1 73 41 1
Eicosapentaenoic acid (EPA) 4 748 56–59 4
Idebenone 1 100 41 1
Levocarnitine 2 33 60,61 1
Triheptanoin 1 23 59 0
Dietary changes 5 288 65–69 0
Note: All CAM RCTs identified through the literature search are identified in this table. All studies were classified as different levels of  evidence 
by AAN guidelines.8 The number of  publications with levels I/II evidence are denoted in the last column. There are multiple CAM modalities 
that did not have any RTCs for their efficacy in HD. The following were specifically searched for without any currently published human 
RTCs: (1) Alternative Medical System (Ayurvedic medicine, aromatherapy, traditional healers, biofeedback, chelation therapy), (2) Mind–body 
interventions (acupuncture, reiki, tai chi, qi gong, guided imagery), and (3) Nutraceuticals/dietary supplementation (epigallo and glutamate).
Abbreviations: AAN, American Academy of  Neurology; CAM, Complementary and Alternative Medicine; EPA, Eicosapentaenoic Acid; 
RCTs, Randomized controlled trial.
Yu M and Bega D Review of CAM and HD
Columbia University Libraries
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org 3
Mind–body interventions
Mind–body therapies access the relationships between the brain, 
mind, body, and behavior to influence health and disease. Many mind–
body interventions involve some form of  relaxation or meditation, 
which may have relevance for psychological and psychosocial stress 
related to HD.9 Basic science work and research in other disease states 
have shown interactions between the endocrine system, immune system, 
autonomic system, and the central nervous system, which could be the 
basis of  health benefits proposed with some CAM modalities.10 Mind–
body activities that have been evaluated in HD include music therapy 
(MT) and dance therapy (DT). As specific exercise interventions have 
not been established as a conventional part of  HD management (unlike 
in other disorders like PD), we include a summary of  the evidence for 
exercise in this review as well.
Music therapy
MT is the use of  music or any of  its elements such as rhythm, melody, 
or harmony with the goal of  meeting physical, emotional, mental, 
social, or cognitive needs.11 MT has been used and studied in many 
neurodegenerative diseases including AD and PD. In AD, MT has been 
associated with improvement in multiple cognitive domains.12 In PD, it 
has been used for social and quality-of-life benefits as well as gait train-
ing.13 Physiological studies have demonstrated increased limbic activity 
in the orbitofrontal cortex and alterations in mesolimbic dopamine 
release on functional MRI (fMRI) in response to music.14 In HD, music 
may have the potential to address abnormal movements as well as qual-
ity-of-life issues that arise from the loss of  expressive and communicative 
skills, especially in advanced disease.
The effects of  MT compared with a recreational therapy control 
intervention in 63 HD patients were studied over 16 weeks.15 No dif-
ferences in communication or behavior between the two groups were 
found.15 Rhythm therapy for HD was also investigated.16 The 
researchers implemented a behavioral intervention involving drum-
ming and rhythm exercises to target early dysexecutive problems in 
10 people (1 preclinical and 9 with early to advanced stages of  HD). 
The study aimed to assess both clinical executive function improve-
ment and changes in the white matter microstructure on MRI. There 
was some evidence for cognitive benefits as well as some changes in 
the callosal white matter microstructure with rhythm therapy, but the 
sample size and the study design limit conclusions.16 Multisensory 
stimulation (MSE) was also studied for HD.17 MSE utilizes a selection 
of  sensory equipment arranged to stimulate a participant’s primary 
senses, without the need for intellectual or structured responses. The 
investigators randomized mid-late staged HD participants to 4 weeks 
of  MSE or relaxation activities and found no significant difference 
between the two groups in measures of  behavior, mood, dyskinesia, or 
physiological measures. The MSE group may have had some positive 
responses during this session on secondary outcomes (the immediate 
effect of  MSE on participant’s mood) but the significance of  this was 
unclear.17
Conclusion: There is insufficient evidence to support the use of  
MT for HD cognitive or motor symptoms. Case reports have described 
benefits on the quality of  life, but this was not clearly replicated in trials. 
There was one Class II study of  MT and one Class III study of  MSE 
that did not demonstrate significant benefits in HD. A small Class III 
study of  rhythm therapy did have positive outcomes on cognitive and 
microstructural changes, but the sample size and the study design limit 
conclusions. Considerations such as group versus individual sessions, 
early versus late-disease participants, and sensitivity of  specific measures 
evaluated may need to be accounted for if  future studies are designed.
Dance therapy
DT uses movements (often in combination with music) therapeuti-
cally to support the intellectual, emotional, and motor functions of  the 
body. Balance and gait deficits impact most patients with manifest HD, 
and DT may target these deficits while providing an enjoyable outlet for 
physical and emotional activities.
Two RCTs have examined the impact of  dance-related interven-
tions on HD symptoms and quality of  life. A study on the effects of  
Dance Dance Revolution (DDR-Harmonix Music Systems 
Incorporated, Cambridge, MA) has been performed.18 In DDR, play-
ers move to targets in response to visual cues seen on a video screen 
that match a song rhythm. The participants enjoyed DDR and 
showed significant improvements in forward walking, backward walk-
ing, and reduced need for gait support compared to when playing a 
handheld game. Contemporary dance in HD for 2 hours per week 
was studied over 5 months. Patients enjoyed the classes and the com-
pliance was high. However, while there was some improvement in 
motor impairment with DT compared with usual care, the neuropsy-
chiatric variables and cognitive outcomes assessed were not improved 
in this study.19
Conclusion: Conventional and unconventional dance therapies 
have been studied in HD. Based on evidence from Class II and Class III 
studies, dance may be a safe and enjoyable activity in patients with HD. 
The beneficial effects of  DT might be limited to motor symptoms and 
more suitable to people with less severe motor and cognitive impair-
ments. Other forms of  dance may need to be studied, and classes specif-
ically tailored to the cognitive and motor needs of  people with HD may 
need to be considered for future trials. In addition, the current data do 
not offer a good consensus for the most beneficial intensity, frequency, 
and duration of  dance intervention in patients with HD. In DT studies 
in patients with PD, it appears that sessions of  60 minutes appear to be 
challenging but manageable while sessions of  90 minutes appear to 
induce some fatigue, causing participants to rest more often during the 
latter portion of  a 90-minute session.20 It is possible that there is a simi-
lar saturation effect in HD, but this is an area that needs further 
elucidation.
Exercise
Physical activity has the potential to impact not only cardiovascular 
health but also aspects of  physical health such as postural control, gait, 
and quality of  life across various neurodegenerative diseases. PD is an 
example of  a disease where exercise was once considered a 
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complementary strategy and has since become a mainstay of  conven-
tional treatment, but practice guidelines have not emphasized exercise 
recommendations in HD to nearly the same extent. In HD mice, tread-
mill exercise has been shown to enhance spatial learning ability and 
slow down hippocampal cell loss.21 HD mice given playgrounds to 
maintain activity had delayed onset of  general health decline compared 
to mice simply given access to food.22 A retrospective analysis of  HD 
patients in Australia and New Zealand demonstrated that lifestyle pas-
sivity was an independent predictor of  age of  HD symptom onset, with 
an average of  4.6 years later onset in the least compared to the most 
passive subjects.23
There are four RCTs involving exercise modalities in HD. 
Importantly, physical activity was not associated with major adverse 
events or injuries in these studies. When injuries occurred, they were 
minimal – mainly back pain and exacerbation of  preexisting unrelated 
cardiac disease.24
The exercise methods ranged from home visits conducted by exercise 
coaches over 16 weeks, 8 weeks of  exercising at home with a DVD, 
9 months of  outpatient multidisciplinary rehabilitation therapy, and 
12 weeks of  an outpatient progressive exercise program.24–27 These 
 studies demonstrate that participants tend to enjoy exercise programs 
regardless of  modality, and improvements in measures of  gait and 
mobility are demonstrated. On the other hand, measures of  postural 
stability and quality of  life did not consistently improve.
Whether patients with HD physiologically respond to exercise differ-
ently from healthy controls has been debated. One study showed that 
patients with HD had higher serum lactate levels after exercise com-
pared to controls.28 On the other hand, endurance training over 26 
weeks demonstrated evidence of  mitochondrial change and muscle 
fiber distribution in people with HD.28 This demonstrated that the 
inherent physical benefit in HD is not necessarily hindered by the dis-
ease process itself. This finding was replicated in another RCT.29
Conclusion: Regular exercise should be recommended to people 
with HD. The general health benefits of  exercise likely extend to HD. 
Most studies investigated supervised exercise programs and showed that 
these were safe. Some benefits for gait measures were seen in Class II 
studies. Future studies should be designed to better understand how 
exercise affects people across all stages of  the disease, and what 
 frequency and methods of  exercise are best suited to HD.30
Alternative medical systems
Alternative medical systems include TCM, Ayurveda, and homeop-
athy, among others. Many are traditions that can be culturally appeal-
ing or familiar to patients who come from specific ethno-cultural 
backgrounds and fulfill a philosophical congruency.31 Others turn to 
alternative systems to deal with limitations in current treatment 
approaches for HD.
TCM is centuries old and is based on the concept of  Yin and Yang 
(two complementary and opposite aspects of  nature). Disease is thought 
to be related to disturbances in Yin (roughly can be translated as “cool”) 
and Yang (roughly can be translated as “heat”). Treatment of  the disease 
often uses herbs to restore balance.32 Only one English-language trial of  
TCM has been published for HD. The herb used in this study, Yi-Gan 
San (YGS), consists of  seven herbs and the original Chinese description 
states that it has a restraining relationship with the liver.33 In TCM, the 
liver is thought to be the organ that stabilizes mental activities and ame-
liorates involuntary muscle movements.33 Improvement on UHDRS 
motor score from 106.3 ± 4.7 to 89.6 ± 5.8 (mean ± SD) was seen in four 
HD patients with severe chorea after taking YGS for 8 weeks.34
There were no RCTs conducted for other alternative medical systems 
like Ayurveda, Qi Gong, or Tai Chi in HD as there had been for PD.35 
This may in part relate to the fact that the overall prevalence of  HD in 
Asia is much lower (0.40/100,000) compared to that in Europe, North 
America and Australia (5.7/100,000).36
Conclusion: There is insufficient evidence to recommend any par-
ticular alternative system or Chinese herb for the management of  HD. 
Based on one small Class III study, further studies of  the herb YGS for 
the management of  chorea should be considered.
Nutraceuticals and dietary adjustments
Multiple lines of  evidence support a role for oxidative stress, inflam-
mation, and mitochondrial dysfunction as part of  a pathogenic cascade 
across neurodegenerative diseases. While mutant huntingtin protein 
lowering and DNA-based therapies are receiving much attention in HD 
disease modification, several industry-led trials have been conducted 
over the recent years in HD to specifically target certain components of  
cell destruction. Likewise, many nutraceuticals and diets are touted as 
impacting oxidative stress, excitotoxicity, and metabolic or mitochon-
drial impairment.37
Antioxidants
Compelling animal data have demonstrated that striatal degenera-
tion in HD may be secondary to excessive activation of  glutamate-gated 
ion channels.38 In studies of  a neuron-like cell line, antioxidants were 
found to be able to protect against glutamate-induced cytolysis.39 Two 
lipophilic, centrally active antioxidants were studied in HD: d-alpha-to-
copheral (vitamin E) and idebenone. Both studies met Class I level of  
evidence criteria, but neither demonstrated improvement on the pre-
defined primary outcomes of  cognition or activities of  daily living 
(ADLs).40,41 CoQ10 is an antioxidant and cofactor related in mitochon-
drial electron transfer. Two large studies of  CoQ10 were stopped for 
futility after failing to demonstrate a difference compared to placebo on 
the rate of  functional decline in HD.42,43
Conclusion: Based on two studies with Class I evidence, it has been 
determined that CoQ10 does not slow the functional decline of  patients 
with HD. From the expanded literature review of  antioxidants, there is 
no further evidence to support the use of  other antioxidants to help ame-
liorate HD symptoms or rate of  progression. There is similar evidence 
against the use of  vitamin E and idebenone based on Class I studies.
Mediating neurotoxicity
Excessive glutamate-mediated neurotoxicity (and likewise insufficient 
GABA) may play a role in the pathophysiological cascade of  HD among 
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other degenerative diseases.44 AOAA can increase brain GABA content 
through inhibiting GABA-T.44 In a study with Class II level of  evidence, 
AOAA supplementation did not show benefit in HD for chorea, gait, cog-
nition, or mood after a 4-month trial. It was proposed that the potential 
side effects of  AOAA (ataxia and drowsiness) may preclude it from being 
increased to a dosage high enough to inhibit CNS GABA-T activity.44 In 
a study of  a GABA precursor (glutamic acid), which crosses the BBB more 
readily than AOAA, motor or cognitive benefits were again not seen.45
The popularity of  cannabis and cannabinoid use in HD among other 
diseases has spread significantly throughout the United States over the 
last few years with the increasing number of  states making cannabis prod-
ucts legal for medicinal or even recreational purposes. The Cannabinoid 
Receptor 1 (CB1) is widespread throughout the central nervous system 
and is densely present in basal ganglia structures.46 Proposed effects of  
cannabinoids on oxidative stress and neuroinflammation make them 
attractive candidates for research in HD and other degenerative diseases, 
but the potential impact of  CB1 receptors on GABA and basal ganglia 
signaling also has implications for the management of  chorea, dystonia, 
and other hyperkinetic movements.46 In HD, the CB1 receptors lose their 
functionality, which leaves the CNS more vulnerable to cytotoxic dam-
age. Loss of  CB1 receptors has been shown to correlate in one study with 
increased mutant huntingtin protein levels.46
A study has been conducted on cannabidiol in HD. Over 6 weeks, an 
average of  700 mg/day did not show improvement in chorea scores, 
although no significant side effects were seen.47 Likewise, no significant 
improvement with the synthetic cannabinoid agonist nabilone for motor 
UHDRS scores when compared to placebo in 44 patients was observed.48 
However, the drug was again described as well tolerated, and there was 
some improvement in chorea (a secondary outcome). Sativex (an extract of  
THC and CBD) had similarly negative findings.49 This again confirmed 
that safety and tolerability were present, but there was no difference found 
on motor, cognitive, behavioral, or functional outcome measures.
Conclusion: There is insufficient evidence to recommend cannabis 
products in the management of  HD. Three studies with Class I level of  
evidence did not demonstrate definitive benefit of  cannabis products, 
but some encouraging results with regard to safety and tolerability as 
well as ongoing accumulation of  anecdotal reports and increasing pop-
ularity and demand across the United States for use for various motor 
and non-motor symptoms suggest a need for larger controlled trials. 
Caution needs to be applied as the safety profile of  cannabis products is 
primarily studied in short-duration studies. The long-term effects on 
cognition and mental health, especially in people with existing neurode-
generative disorders, are not established.
Metabolic dysfunction
HD is a hypercatabolic state resulting in energy deficiency and weight 
loss. Animal models have demonstrated anti-dyskinetic effects of  com-
pounds that are in the highly unsaturated fatty acids (HUFA) class.50 
HUFA and creatine supplementation in rat models have slowed motor 
deterioration and significantly reduced brain atrophy and improved sur-
vival by 20%.50 Both compounds influence various receptors, ion chan-
nels, muscle function, and various enzymes.50
Creatine supplementation has been studied in multiple RCTs, includ-
ing one trial that meets Class I level of  evidence criteria.51–54 That trial 
tested a creatine dose of  5 g/day with no improvement in motor, cogni-
tion, or coordination ability.51 A later trial, CREST-E, used a higher 
dose up to 40 g/day.52 Not only was no benefit seen at that higher dose, 
but also gastrointestinal side effects occurred with higher likelihood.
With regard to fatty acids, eicosapentaenoic acid (EPA) is the most 
studied. There are promising data on EPA from four RCTs, two of  
which meet criteria for Class I level of  evidence.55–58 While significant 
improvement in motor functioning was not demonstrated in all trials, 
one trial did demonstrate an improvement in the presence of  orofacial 
dyskinesia and MR imaging demonstrated improvement in progressive 
cerebral atrophy that is the natural history of  HD.57 The two patients on 
placebo and screened with MRI had an increase in ventricular size, 
while the two patients on EPA had a decrease in ventricular size after 6 
months.57 There is also an abnormal brain energy profile in HD patients, 
and supplementation with triheptanoin (a metabolic intermediate of  
branched-chain amino acids) was able to improve this abnormal pro-
file.59 When a combination of  fatty acids was used (up to 8 g daily), there 
was an improvement in overall dyskinesia and UHDRS-motor scores. 
However, the functional scales and cognitive-behavioral outcomes were 
not significantly improved.
Levocarnitine is also a regulator of  lipid metabolism with reported 
antioxidant properties. The two studies targeting levocarnitine in 
patients with HD demonstrated that levocarnitine supplementation 
may only be beneficial in those with hypocarnitinemia.60,61
Conclusion: There is Class I evidence that creatine does not slow 
down disease progression or improve symptoms of  HD. Subsequent tri-
als have been conducted and further support these recommendations. 
More data are needed to clarify recommendations surrounding fatty 
acid supplementation. Two Class I studies demonstrate no significant 
benefit from these compounds, and this is reflected in the AAN guide-
lines. Since that publication, more data have come out to suggest that 
fatty acid supplementation should be studied more for the potential to 
impact dyskinesias as well as the overall rate of  cerebral atrophy. 
Levocarnitine may only be helpful for a certain subset of  HD patients 
with specific metabolic abnormalities.
Dietary changes
As HD is a systemic disease, patients often have metabolic changes 
and challenges particularly with unintentional weight loss and muscle 
wasting. HD is also an energy-deficient state, and it is important to find 
ways to provide proper high-calorie nutrition to HD patients.62 Clinically, 
a higher baseline BMI has been positively associated with slower rates 
of  deterioration in multiple domains: motor, functional, and 
cognitive.63
Typically, high calorie diets are recommended for patients with HD 
to meet metabolic demands. Diets that contain high levels of  certain 
antioxidants and nutrients have raised interest in neurodegenerative dis-
ease, as have ketogenic diets. Ketogenic diet was suggested to delay 
weight loss in a mouse model of  HD, but human studies are not avail-
able.64 High-protein diets are generally well tolerated, but while the 
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increased calorie count does improve body weight, there was no signifi-
cant change in motor or cognitive functioning.65,66
The impact of  targeted, individualized dietary therapy has been 
studied in patients with HD. The biologic basis for their study comes 
from the idea that microRNAs (miRNAs) could potentially be used as a 
biomarker in HD. miRNAs are small non-coding RNAs and are upreg-
ulated in HD.67 It is believed to demonstrate a potential impairment in 
the cholesterol metabolism pathway in HD. Other studies have also 
demonstrated that certain dietary factors, like a diet high in dairy prod-
uct, could speed up the rate of  phenoconversion, leading to an earlier 
age of  onset.68 This individualized diet (rich in uric acids, GABA, anti-
oxidants, and branched chain amino acids) had high adherence over the 
12 months of  the trial and led to both a noticeable increase in fat mass 
and a decrease in the expression of  miRNAs. Both cognitive and motor 
status improved in a few of  the participants as well.65 A similar biochem-
ical improvement was replicated after supplementation of  the diets of  
people with HD with triheptanoin, which is an important intermediate 
of  the Kreb’s cycle.69 Normally, HD patients more quickly develop mus-
cle acidosis after exercise, but just 4 days of  a trihepatanoin-enriched 
diet was able to normalize the muscle pH.69
Conclusion: High-calorie diets are typically recommended in HD, 
but no specific diet can be endorsed at this time. Individualizing diets 
may be important. More research needs to be done to understand dif-
ferent energy profiles in individual patients and how certain diets could 
be beneficial to their disease course.
Discussion
CAM modalities are frequently utilized by patients with neurode-
generative diseases, but physicians lack the knowledge and evidence to 
guide patients into safe practices.5 Our review shows a relative paucity 
of  clinical trials examining CAM modalities in HD when compared to 
other neurodegenerative disorders like AD or PD. Regarding alterna-
tive medical systems, almost no data is available possibly due to cul-
tural and epidemiological differences and the relative rarity of  the 
disease. CAM is particularly important for HD as currently there are 
no good conventional therapies, so the need for other modalities of  
treatment is even more pressing. Mind–body interventions such as 
dance and exercise are proposed to impact motor and quality of  life in 
HD, but more evidence supporting specific interventions is needed. 
Supervised exercise and contemporary dance have been shown to be 
safe for people with HD, and some motor benefits have been demon-
strated, but specific recommendations for class structure, frequency, 
and range of  exercise and dance styles cannot be commented on. 
More robust trials should be conducted for other mind–body interven-
tions such as acupuncture and Tai Chi for which no clinical trial data 
were available. A recent qualitative study on yoga reported that 
patients with HD are interested in yoga participation if  it can be tai-
lored to make it safe for them.70 Participants in various mind–body 
interventions tend to enjoy the process but determining the appropri-
ate stage for intervention in HD may also be important to consider for 
future trials, as advanced patients may not have the same benefits as 
early stage patients.
Despite having good animal model data and strong biological basis 
for nutraceutical supplements, there is no evidence supporting disease 
modification or symptom improvement with any specific supplement in 
HD clinical trials. Cannabis products, fatty acids, and individualized 
diets were raised as potential areas worthy of  further research.
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Appendix A
“huntington+complementary”: 1
“huntington+CAM”: 0
“huntington+integrative”: 1
“huntington+aromatherapy”: 0
“huntington+acupuncture”: 0
“huntington+diet”: 8
“huntington+nutraceuticals”: 6
“huntington+dance”: 2
“huntington+Chinese”: 1
“huntington+Indian”: 0
“huntington+herb”: 0
“huntington+cannabis”: 1
“huntington+cannabidiol”: 2
“huntington+reiki”: 0
“huntington+epigallo”: 0
“huntington+nabilone”: 1
“huntington+behavior”: 9
“huntington+tai chi”: 0
“huntington+energy”: 5
“huntington+natural”: 0
“huntington+breathing”: 0
“huntington+qi gong”: 0
“huntington+massage”: 0
“huntington+meditation”: 0
“huntington+manipulation”: 0
“huntington+meditation”: 0
“huntington+homeopathy”: 0
“huntington+relax”: 1
“huntington+fish+oil”: 5
“huntington+oil”: 1
“huntington+exercise”: 9
“huntington+therapy”: 21
“huntington+vitamin”: 4
“huntington+supplement”: 3
“huntington+biofeedback”: 0
“huntington+osteopathic”: 0
“huntington+heal”: 0
“huntington+hypnosis”: 0
“huntington+plant”: 1
“huntington+Feldenkrais”: 0
“huntington+Alexander”: 0
“huntington+technique”: 1
“huntington+yoga”: 0
“huntington+trager”: 0
“huntington+pilates”: 0
“huntington+naturopathy”: 0
“huntington+botanical”: 1
“huntington+curandero”: 0
“huntington+espiritista”: 0
“huntington+hierbero”: 0
“huntington+shaman”: 0
“huntington+sobador”: 0
“huntington+imagery”: 0
